Insider buying last 90 days
No open-market insider purchases were filed for KNSA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Kiniksa Pharmaceuticals International closed at $98.76 on 9 November 2026, +5.2% on the day. The price sits above both the 50-day ($80.88) and 200-day ($61.79) moving averages, inside a 52-week range of $37.02 to $99.31. The GekkoIndex reads 50, in the Neutral zone, up 4.1 points over five sessions. Gekko Fair Value is $92.05, so the price is 7.3% above it.
The next earnings report is due on 23 February 2027, 100 days away (before open). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 16.8% across the report. Seasonally, the next 20 trading days from this point averaged -0.8% over the last 5 years, rising in 3 of them.
5 firms rate the stock: 5 buy, 0 hold and 0 sell, with a consensus target of $109.43. A typical daily move is about 6.4%, and a typical 20-day move about 7.9%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (fair value).
A plain summary of the figures as of the Nov 9, 2026 close.
Kiniksa Pharmaceuticals International scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive3 mixed0 headwinds
Above 50 and 200-day
Close $96.33 is above the 50-day ($82.18) and 200-day ($62.83) averages, and the 50-day is above the 200-day.
See the chart52.5, Neutral
Reading 52.5 is in the Neutral zone.
See the GekkoIndex3.5% above
Price is within 5% of Gekko Fair Value (3.5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings−0.2% on average
From this point in the calendar, the next 20 trading days averaged −0.2% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Kiniksa Pharmaceuticals International closed at $96.33 on Nov 13, 2026, +137.4% over the past year, inside a 52-week range of $37.02 to $99.31.
Use the left and right arrow keys to read daily values.
Put KNSA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Kiniksa Pharmaceuticals International develops and sells medical treatments, working across the United States, the United Kingdom, and other countries. Its established product is ARCALYST, a cytokine-trapping therapy that targets interleukin-1alpha and 1beta and is used to treat recurrent pericarditis, an inflammatory heart condition, as well as cardiac sarcoidosis.
Beyond its marketed therapy, the company is advancing a pipeline of antibody-based candidates. KPL-387, a fully human monoclonal antibody, is being studied in a combined Phase 2/3 trial for recurrent pericarditis, while KPL-116, an Fc-modified monoclonal antibody, remains in earlier pre-clinical development. The company was previously called Kiniksa Pharmaceuticals, Ltd. before adopting its current name in June 2024.
Founded in 2015, Kiniksa Pharmaceuticals International is headquartered in London, United Kingdom. Its shares trade on the NASDAQ under the ticker KNSA.
Kiniksa Pharmaceuticals International’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.5, in the Neutral zone, up 1.6 points over five sessions.
Up 1.6 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | +3.5% | +14.3% | ||
| Accumulation | 149 | +2.6% | +8.3% | ||
| Neutral (current zone) | 464 | +1.0% | +4.1% | ||
| Distribution | 58 | +0.2% | +1.5% | ||
| Selling | 4 | Too few readings yet | |||
Average KNSA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Kiniksa Pharmaceuticals International trades 3.5% above Gekko Fair Value of $93.08, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Kiniksa Pharmaceuticals International shares are worth, recalculated every trading day.
$93.08
Gekko Fair Value, Nov 14, 2026
3.5% above fair value · About fair value
At the end of Aug 2026 the price was 10.9% below the estimate.
No open-market insider purchases were filed for Kiniksa Pharmaceuticals International, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for KNSA in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in KNSA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Kiniksa Pharmaceuticals International has been buying back its own shares.
From company filings.
Kiniksa Pharmaceuticals International reports on Feb 23, 2027, before the open (100 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 23, 2027
Expected before the open, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 27, 2026 | $0.56 est $0.37 | $286.0M est $260.7M | +30.4% |
| Jul 28, 2026 | $0.30 est $0.30 | $243.6M est $226.5M | +27.4% |
| Apr 28, 2026 | $0.27 est $0.18 | $214.3M est $206.1M | +21.5% |
| Feb 24, 2026 | $0.17 est $0.29 | $202.1M est $200.8M | −9.8% |
| Oct 28, 2025 | $0.23 est $0.32 | $180.9M est $197.1M | −7.9% |
| Jul 29, 2025 | $0.23 est $0.18 | $156.8M est $166.5M | +11.2% |
| Apr 29, 2025 | $0.11 est $0.02 | $137.8M est $131.9M | +25.6% |
| Feb 25, 2025 | −$0.12 est $0.02 | $122.5M est $123.4M | +0.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Kiniksa Pharmaceuticals International is $109.43, +13.6% from the last close, from 5 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 5 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 30 | J.P. Morgan | $122 | +26.6% |
| Oct 28 | Wells Fargo | $110 | +14.2% |
| Oct 28 | Canaccord Genuity | $98 | +1.7% |
| Oct 27 | Goldman Sachs | $101 | +4.8% |
| Oct 23 | Canaccord Genuity | $98 | +1.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Kiniksa Pharmaceuticals International averaged −0.2% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.5% | 2 of 5 |
| Next 10 trading days | −1.6% | 2 of 5 |
| Next 15 trading days | +0.9% | 3 of 5 |
| Next 20 trading days | −0.2% | 3 of 5 |
| Next 30 trading days | −1.9% | 2 of 5 |
For scale, KNSA’s typical 20-trading-day move in either direction is about 8%.
Kiniksa Pharmaceuticals International’s market cap is $7.57B, with a P/E ratio of 72.4 and revenue of $946.0M over the last twelve months.
Coverage of Kiniksa Pharmaceuticals International this week reads negative: 0 positive, 1 neutral and 2 negative headlines.
Kiniksa Pharmaceuticals International’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Kiniksa Pharmaceuticals International’s market cap is $7.57B at the Nov 13, 2026 close of $96.33, with 48.84M shares outstanding. The shares trade on a P/E ratio of 72.4.
The consensus analyst 12-month price target for Kiniksa Pharmaceuticals International is $109.43, +13.6% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Kiniksa Pharmaceuticals International is about fair value: the Nov 13, 2026 close of $96.33 is 3.5% above Gekko Fair Value of $93.08. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Kiniksa Pharmaceuticals International is expected to report on Feb 23, 2027, before the market opens (100 days away). Analysts expect earnings of $0.25 per share on revenue of $306.6M. Kiniksa Pharmaceuticals International beat the earnings estimate in 5 of its last 8 reports, moving 16.8% on average across the report.
Kiniksa Pharmaceuticals International’s 52-week high is $99.31 and its 52-week low is $37.02; it closed at $96.33 on Nov 13, 2026, +137.4% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 3 as mixed (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.